α-Synuclein pathology in the spinal cord autonomic nuclei associates with α-synuclein pathology in the brain: a population-based Vantaa 85+ study
- 147 Downloads
In most subjects with Parkinson’s disease and dementia with Lewy bodies, α-synuclein (αS) immunoreactive pathology is found not only in the brain but also in the autonomic nuclei of the spinal cord. However, neither has the temporal course of αS pathology in the spinal cord in relation to the brain progression been established, nor has the extent of αS pathology in the spinal cord been analyzed in population-based studies. Using immunohistochemistry, the frequency and distribution of αS pathology were assessed semiquantitatively in the brains and spinal cord nuclei of 304 subjects who were aged at least 85 in the population-based Vantaa 85+ study. αS pathology was common in the spinal cord; 102 (34%) subjects had classic αS pathology in the thoracic and/or sacral autonomic nuclei. Moreover, 134 (44%) subjects showed grain- or dot-like immunoreactivity in neuropil (mini-aggregates) without classic Lewy neurites or Lewy bodies (LBs). The latter type of αS accumulation is associated with age, but also the classic αS pathology was found more often in the oldest compared to the youngest age group. The severity of αS pathology in the spinal cord autonomic nuclei is significantly associated with the extent and severity of αS pathology in the brain. Of the subjects, 60% with moderate to severe thoracic αS pathology and up to 89% with moderate to severe sacral αS pathology had diffuse neocortical type of LB pathology in the brain. αS pathology exclusively in the spinal cord was rare. Our study indicates that in general αS pathology in the spinal cord autonomic nuclei is associated with similar pathology in the brain.
Keywordsα-Synuclein Spinal cord Dementia with Lewy bodies Parkinson’s disease Population-based study αS pathology Lewy-related pathology
The authors thank Mrs Tuija Järvinen for excellent technical assistance. This study was financially supported by the Finnish Medical Foundation and the Helsinki University Central Hospital competitive research fund (EVO).
Conflict of interest statement
The authors report no conflicts of interest.
- 2.Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL III, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, Walker DG, Arizona Parkinson’s Disease Consortium (2009) Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol (Berl) 117:613–634CrossRefGoogle Scholar
- 7.Braak H, Muller CM, Rub U, Ackermann H, Bratzke H, de Vos RA, Del Tredici K (2006) Pathology associated with sporadic Parkinson’s disease—where does it end? J Neural Transm Suppl 70:89–97Google Scholar
- 15.McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124PubMedGoogle Scholar
- 16.McKeith IGFM, Dickson DW, Lowe JDM, Emre M, O’Brien JTDM, Feldman HCM, Cummings J, Duda JE, Lippa C, Perry EKDS, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJFRCP, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier SFRCPC, Goetz CG, GomezTortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RNFRCP, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VMY, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, MukaetovaLadinska EB, Pasquier F, Perry RHDS, Schulz JB, Trojanowski JQ, Yamada M, for the Consortium on DLB (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 65:1863–1872CrossRefPubMedGoogle Scholar